Literature DB >> 2723120

Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy.

S N Anavekar1, L G Howes, B Jarrott, M Syrjanen, E L Conway, W J Louis.   

Abstract

Using a sensitive and specific radioimmunoassay the pharmacokinetic disposition of clonidine was determined in hypertensive patients after a single dose and then after 5, 28 and 56 days of chronic dosing with 75 micrograms bd. Following a single dose of clonidine maximal plasma concentrations of 0.34 +/- 0.06 ng/ml were achieved after 3.6 +/- 1.2 hours. After 5 days of repetitive dosing the maximal concentration was significantly higher, 0.66 +/- 0.06 ng/ml and remained so throughout chronic therapy (P = 0.018). The AUC, Tmax and T1/2 did not differ significantly between the acute dose and the chronic dosing pharmacokinetic studies. Clonidine also produced a significant fall in blood pressure. Supine diastolic blood pressure fell from 106 +/- 5 mmHg predose to 99 +/- 6 mmHg 2 hours after the first dose (P less than 0.05). The corresponding values after cyclopenthiazide alone were 108 +/- 8 and 105 +/- 8 mmHg (P = 0.13). Similar falls in blood pressure were produced during chronic therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723120     DOI: 10.1002/j.1552-4604.1989.tb03335.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 2.  Central sympatholytic drugs.

Authors:  Wanpen Vongpatanasin; Kazuomi Kario; Steven A Atlas; Ronald G Victor
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-18       Impact factor: 3.738

3.  The pharmacokinetics of clonidine in high dosage.

Authors:  J Fauler; L Verner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial.

Authors:  Even Fagermoen; Dag Sulheim; Anette Winger; Anders M Andersen; Nils Tore Vethe; J Philip Saul; Erik Thaulow; Vegard Bruun Wyller
Journal:  BMC Res Notes       Date:  2012-08-07

5.  Rocuronium-induced neuromuscular block after long pretreatment of clonidine in rabbits.

Authors:  Min Seok Koo; Nam Yun Kim; Hee Jong Lee; Sung Wook Yoon; Kyo Sang Kim
Journal:  Korean J Anesthesiol       Date:  2010-09-20

6.  Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts.

Authors:  Xiao-Li Zhang; Gui-Bin Wang; Li-Yan Zhao; Li-Li Sun; Jun Wang; Ping Wu; Lin Lu; Jie Shi
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

7.  The protocol of the Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial.

Authors:  Bjørn Erik Neerland; Karen Roksund Hov; Vegard Bruun Wyller; Eirik Qvigstad; Eva Skovlund; Alasdair M J MacLullich; Torgeir Bruun Wyller
Journal:  BMC Geriatr       Date:  2015-02-10       Impact factor: 3.921

8.  Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial.

Authors:  Even Fagermoen; Dag Sulheim; Anette Winger; Anders M Andersen; Johannes Gjerstad; Kristin Godang; Peter C Rowe; J Philip Saul; Eva Skovlund; Vegard Bruun Wyller
Journal:  BMC Pediatr       Date:  2015-09-10       Impact factor: 2.125

9.  The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses.

Authors:  Karen Roksund Hov; Bjørn Erik Neerland; Anders Mikal Andersen; Øystein Undseth; Vegard Bruun Wyller; Alasdair M J MacLullich; Eva Skovlund; Eirik Qvigstad; Torgeir Bruun Wyller
Journal:  BMC Pharmacol Toxicol       Date:  2018-06-08       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.